PARK7 and cancer: It is important to point out that while a good majority of cancers exhibit p53 mutation that can render p53 null or p53 inactive status,[56] p53 too plays an important role in cancer ferroptosis.[51, 52, 54] Recent evidences show that Park7 upregulation confers protection against ferroptosis in cancer cells.[20] Thus, together with our data, it is not unexpected to predict that more ferroptotic damage occurs in other healthy organs compared to cancer cells when patients are subjected to DOX treatment.